
        <!DOCTYPE html>
        <html>
        <head>
            <title>ULTRAGENYX PHARMACEUTICAL INC. (RARE) - Articles</title>
            <meta name="viewport" content="width=device-width, initial-scale=1.0">
            <style>
                :root {
                    --primary-color: #000000;
                    --secondary-color: #666666;
                    --accent-color: #d5001c;
                    --text-color: #2c3e50;
                    --border-color: #e0e0e0;
                    --hover-color: #f8f9fa;
                }
                
                body { 
                    font-family: "Porsche Next", "Segoe UI", Arial, sans-serif;
                    margin: 0;
                    padding: 0;
                    color: var(--text-color);
                    background-color: #f5f6fa;
                    line-height: 1.6;
                }
                
                .header {
                    background: linear-gradient(135deg, #000 0%, #1a1a1a 100%);
                    padding: 25px 0;
                    box-shadow: 0 2px 10px rgba(0,0,0,0.2);
                    position: sticky;
                    top: 0;
                    z-index: 1000;
                    backdrop-filter: blur(10px);
                }
                
                .header::before {
                    content: '';
                    position: absolute;
                    top: 0;
                    left: 0;
                    right: 0;
                    bottom: 0;
                    background: radial-gradient(circle at 30% 50%, rgba(255,255,255,0.08) 0%, rgba(255,255,255,0) 70%);
                    pointer-events: none;
                }
                
                .header-content {
                    max-width: 1400px;
                    margin: 0 auto;
                    padding: 0 30px;
                    display: flex;
                    justify-content: space-between;
                    align-items: center;
                }
                
                .header-title {
                    font-size: 28px;
                    font-weight: 300;
                    color: #fff;
                    margin: 0;
                    letter-spacing: 1px;
                }
                
                .back-btn {
                    background: rgba(255,255,255,0.1);
                    border: 1px solid rgba(255,255,255,0.2);
                    padding: 10px 20px;
                    color: #fff;
                    text-decoration: none;
                    font-size: 14px;
                    border-radius: 4px;
                    transition: all 0.3s ease;
                    backdrop-filter: blur(5px);
                }
                
                .back-btn:hover {
                    background: rgba(255,255,255,0.2);
                    transform: translateY(-2px);
                }
                
                .container {
                    max-width: 1400px;
                    margin: 40px auto;
                    padding: 0 30px;
                }
                
                .stats-container {
                    display: grid;
                    grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
                    gap: 20px;
                    margin-bottom: 40px;
                }
                
                .stat-card {
                    background: #fff;
                    border-radius: 12px;
                    padding: 25px;
                    text-align: center;
                    box-shadow: 0 4px 20px rgba(0,0,0,0.08);
                    transition: transform 0.3s ease;
                }
                
                .stat-card:hover {
                    transform: translateY(-5px);
                }
                
                .stat-value {
                    font-size: 32px;
                    font-weight: 300;
                    color: var(--primary-color);
                    margin-bottom: 10px;
                }
                
                .stat-label {
                    font-size: 14px;
                    color: var(--secondary-color);
                    text-transform: uppercase;
                    letter-spacing: 1px;
                }
                
                .articles-grid {
                    display: grid;
                    grid-template-columns: repeat(auto-fill, minmax(400px, 1fr));
                    gap: 30px;
                    margin-top: 40px;
                }
                
                .article-card {
                    background: #fff;
                    border-radius: 12px;
                    overflow: hidden;
                    box-shadow: 0 4px 20px rgba(0,0,0,0.08);
                    transition: all 0.3s ease;
                }
                
                .article-card:hover {
                    transform: translateY(-5px);
                }
                
                .article-content {
                    padding: 25px;
                }
                
                .article-title {
                    font-size: 18px;
                    font-weight: 400;
                    margin: 0 0 15px;
                    line-height: 1.4;
                }
                
                .article-title a {
                    color: var(--primary-color);
                    text-decoration: none;
                    transition: color 0.2s ease;
                }
                
                .article-title a:hover {
                    color: var(--accent-color);
                }
                
                .article-meta {
                    display: flex;
                    align-items: center;
                    gap: 20px;
                    margin-bottom: 15px;
                    font-size: 14px;
                    color: var(--secondary-color);
                }
                
                .article-sentiment {
                    padding: 4px 12px;
                    border-radius: 20px;
                    font-weight: 500;
                    font-size: 14px;
                }
                
                .article-sentiment.positive {
                    background: rgba(40,167,69,0.1);
                    color: #28a745;
                }
                
                .article-sentiment.negative {
                    background: rgba(220,53,69,0.1);
                    color: #dc3545;
                }
                
                .article-sentiment.neutral {
                    background: rgba(108,117,125,0.1);
                    color: #6c757d;
                }
                
                .article-summary {
                    font-size: 14px;
                    color: var(--text-color);
                    line-height: 1.6;
                    margin-top: 15px;
                    opacity: 0.8;
                }
                
                @media (max-width: 768px) {
                    .header-content {
                        padding: 0 20px;
                    }
                    
                    .header-title {
                        font-size: 20px;
                    }
                    
                    .container {
                        padding: 0 20px;
                        margin: 20px auto;
                    }
                    
                    .articles-grid {
                        grid-template-columns: 1fr;
                        gap: 20px;
                    }
                    
                    .stat-card {
                        padding: 20px;
                    }
                    
                    .stat-value {
                        font-size: 28px;
                    }
                }
            </style>
        </head>
        <body>
            <div class="header">
                <div class="header-content">
                    <h1 class="header-title">ULTRAGENYX PHARMACEUTICAL INC. (RARE)</h1>
                    <a href="sentiment_report_latest.html" class="back-btn">← Back to Dashboard</a>
                </div>
            </div>
            
            <div class="container">
                <div class="stats-container">
                    <div class="stat-card">
                        <div class="stat-value">21</div>
                        <div class="stat-label">Total Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">10</div>
                        <div class="stat-label">Positive Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">5</div>
                        <div class="stat-label">Negative Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">0.18</div>
                        <div class="stat-label">Average Sentiment</div>
                    </div>
                </div>
                
                <div class="articles-grid">
        
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=3b39122eb10efe9b362d93dab8b46f21d6ef5030b627bccb8c95efa4c96c48b4" target="_blank" rel="noopener noreferrer">Mereo BioPharma Group (MREO) Announced Progress in the Phase 3 Orbit Study Testing UX143</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-11</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.35
                                </span>
                            </div>
                            <div class="article-summary">Mereo BioPharma Group plc (NASDAQ:MREO) is one of the Best 52-Week Low Penny Stocks to Buy Now. On July 9, Mereo BioPharma Group, along with Ultragenyx Pharmaceutical Inc., announced progress in the P...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=aa819c604e4f62ba924f337b8e60fef2c6fcb8ebc0b9babdb0ac2ccc347278d4" target="_blank" rel="noopener noreferrer">Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-08</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.15
                                </span>
                            </div>
                            <div class="article-summary">NasdaqGS:RARE 1 Year Share Price vs Fair Value Explore Ultragenyx Pharmaceutical's Fair Values from the Community and......</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=fb699f9cf9909c41ee02a5d5f07acb9380a6e80799e644422803de322d0d3a42" target="_blank" rel="noopener noreferrer">Ultragenyx Pharmaceutical Second Quarter 2025 Earnings: Beats Expectations</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-07</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.78
                                </span>
                            </div>
                            <div class="article-summary">NasdaqGS:RARE 1 Year Share Price vs Fair Value Explore Ultragenyx Pharmaceutical's Fair Values from the Community and......</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=e8907034a17f35dae0f23a135bec5ca8fee0003e570386a33158514a17a97691" target="_blank" rel="noopener noreferrer">Ultragenyx Pharmaceutical Inc. (RARE) Q2 2025 Earnings Call Transcript</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-06</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ETCompany ParticipantsEmil D....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=da3d4ba3b7a7e0534f2df2bc28731d3f14914cd2ef34436a745a21b055acaca4" target="_blank" rel="noopener noreferrer">Ultragenyx Pharmaceutical Inc (RARE) Q2 2025 Earnings Call Highlights: Strong Revenue Growth ...</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-06</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.95
                                </span>
                            </div>
                            <div class="article-summary">Ultragenyx Pharmaceutical Inc (RARE) reports a 13% revenue increase in Q2 2025, driven by robust product sales, despite a net loss and high operating expenses....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=7617ebe77f199aa474496bd605028449a8c26e9f1a9acc352366272efc9da4d0" target="_blank" rel="noopener noreferrer">Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-06</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.77
                                </span>
                            </div>
                            <div class="article-summary">RARE posts a narrower Q2 loss and 13% revenue growth as demand rises across all four marketed rare disease drugs....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=782b324bf2dfc233e7c8afc9f69525ba630c508c2fc22cef2dc8d076e21f2c39" target="_blank" rel="noopener noreferrer">Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-05</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.35
                                </span>
                            </div>
                            <div class="article-summary">Second quarter total revenue of $166 million,Crysvita® revenue of $120 million and Dojolvi® revenue of $23 million Reaffirm 2025 Revenue Guidance: Total revenue between $640 million to $670 million, C...</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=4c4db55ceff6aebc443f0d3410aa7a30dd7540490cbf1b23e46f9fcb73b08975" target="_blank" rel="noopener noreferrer">Ultragenyx: Q2 Earnings Snapshot</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-05</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment negative">
                                    -0.57
                                </span>
                            </div>
                            <div class="article-summary">RARE) on Tuesday reported a loss of $115 million in its second quarter. On a per-share basis, the Novato, California-based company said it had a loss of $1.17. The results exceeded Wall Street expecta...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=c5a4640f4630e60fe50d6a36fc899c6de68f9c59ad324d0760e8bcabe0f77657" target="_blank" rel="noopener noreferrer">Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-05</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Stree...</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=5013caafa4bffef30516f7db8beebb6a7c4d52a37ea6537585137899dfd3ec5d" target="_blank" rel="noopener noreferrer">Ultragenyx Pharmaceutical Inc. (RARE): A Bull Case Theory</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-04</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment negative">
                                    -0.56
                                </span>
                            </div>
                            <div class="article-summary">We came across a bullish thesis on Ultragenyx Pharmaceutical Inc. on Valueinvesting subreddit by bluespacecolombo. In this article, we will summarize the bulls’ thesis on RARE. Ultragenyx Pharmaceutic...</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=d00d8ff8841c65a07ed2cc66e5e25ca4edcea942ca00d5e4d487d4e46ae93258" target="_blank" rel="noopener noreferrer">Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-31</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment negative">
                                    -0.38
                                </span>
                            </div>
                            <div class="article-summary">Verastem (VSTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=d8d03f8c8aa87422bdee5aa632f0564b376b62a6ee3494e8033b2eed90c0a6c4" target="_blank" rel="noopener noreferrer">Ultragenyx Pharmaceutical Inc. (RARE) Gets FDA CRL for UX111, Vows Quick Resubmission</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-31</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.33
                                </span>
                            </div>
                            <div class="article-summary">We recently compiled a list of 11 Best Future Stocks to Buy Now. Ultragenyx Pharmaceutical Inc. stands first on our list. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), based in Novato, California, foc...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=e2c16c456e925f71a0b7e4ba5cd6449f9c029d6e7399f29ab83fe04c7d0bf33e" target="_blank" rel="noopener noreferrer">Ultragenyx Completes Enrollment of Phase 3 Aspire Study Evaluating GTX-102 for the Treatment of Angelman Syndrome</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-31</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.67
                                </span>
                            </div>
                            <div class="article-summary">Company expects to complete Phase 3 Aspire study in the second half of 2026 Aurora study of GTX-102 in additional ages and genotypes on track to initiate in the second half of 2025 NOVATO, Calif., Jul...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=6a7468317709f8aaee7431020da3226a5e2740d80776396df5cb6886919fc22f" target="_blank" rel="noopener noreferrer">Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-30</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">NOVATO, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for seri...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=96134747ecd66aa35ff15dd889e8eb923a856ff6470b42e32309c53d56e69322" target="_blank" rel="noopener noreferrer">Ultragenyx: July Selloff Creates Buying Opportunity Ahead Of UX143 Catalyst</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-29</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment positive">
                                    0.36
                                </span>
                            </div>
                            <div class="article-summary">Ultragenyxâs 35% July selloff is overblown; both UX143 and UX111 programs remain on track with key catalysts ahead. Learn more on RARE stock here....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=e57c5ce57b0c448a894ed1ba5a6f113eeeb59d4fbc3bc765775d170c9958dbc1" target="_blank" rel="noopener noreferrer">BioHarvest Sciences Inc. (BHST) Surges 5.6%: Is This an Indication of Further Gains?</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-24</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.95
                                </span>
                            </div>
                            <div class="article-summary">BioHarvest Sciences Inc. (BHST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further p...</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=d600dfc54a414f76e065c24f2c0cdb2127e0d72112cbdd15cb61aba0b8a8007f" target="_blank" rel="noopener noreferrer">FDA Rejects Replimune’s Skin Cancer Treatment, Shares Sink</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-22</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment negative">
                                    -0.55
                                </span>
                            </div>
                            <div class="article-summary">(Bloomberg) -- Replimune Group Inc. shares sank to their lowest point ever after US regulators rejected a skin cancer treatment from the biotech company, another sign of the agency’s new leadership ta...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=569c2622e58f961bea6777d7d920c41af04a8ea3d8bb31cb463741c3dd9c3aa8" target="_blank" rel="noopener noreferrer">Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-18</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">NOVATO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rar...</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=35d6c4e97201fd29b6821e5039c985469fe35feac3c5f5558426a055307523e3" target="_blank" rel="noopener noreferrer">Bank of America Securities Reiterated a Buy Rating on Ultragenyx Pharmaceutical (RARE)</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-17</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment negative">
                                    -0.30
                                </span>
                            </div>
                            <div class="article-summary">Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the Best 52-Week Low Stocks to Buy According to Analysts. On July 14, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Ult...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=42b6f344f1d7bf633f17ac5d791d76235d2a8198d8b686710acdf9bb6e19fea8" target="_blank" rel="noopener noreferrer">New Pedestrian Access from Inner Belt to East Somerville MBTA Station Now Open to the Public</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-16</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.48
                                </span>
                            </div>
                            <div class="article-summary">The City of Somerville, MBTA, and developers North River Leerink and Wheelock Street Capital are pleased to announce a new pedestrian connection between the MBTA's East Somerville Green Line Station a...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=722a1eabdcfc289edbe915afd2147f8b9c4722179696aee8ff58acb6b546a7c9" target="_blank" rel="noopener noreferrer">William Blair Maintains a Buy on Ultragenyx Pharmaceutical (RARE)</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-16</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the best oversold NASDAQ stocks to buy now. On July 14, William Blair analyst Sami Corwin maintained a bullish stance on Ultragenyx Pharmaceutica...</div>
                        </div>
                    </div>
            
                </div>
            </div>
        </body>
        </html>
        